MDX-1097 is under clinical development by HaemaLogix and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData, Phase II drugs for Refractory Multiple Myeloma have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MDX-1097’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KappaMab (IST-1097, MDX-1097) is under development for the treatment of relapsed/refractory multiple myeloma. The drug candidate is administered as an intravenous infusion. The drug candidate is a chimeric monoclonal antibody. It specifically recognizes a cell surface antigen designated kappa myeloma antigen (KMA) expressed on multiple myeloma (MM) cell lines and malignant plasma cells isolated from MM and Waldenstrom's macroglobulinemia patients. The therapeutic candidate was also under development for primary amyloidosis, Waldenstrom's macroglobulinemia and lymphoma.
HaemaLogiX Pty. Ltd is a pharmaceuticals and healthcare based company which is researching immune-based treatments that target unique antigens on malignant cells to improve the quality of life of patients suffering from blood cancers. The company is headquartered in Eveleigh, New South Wales, Australia.
For a complete picture of MDX-1097’s drug-specific PTSR and LoA scores, buy the report here.